ArticleTranslational oncology2026
Integrating spatial and single-cell transcriptomics via machine learning to characterize efferocytosis in hepatocellular carcinoma prognosis and immunotherapy.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Context-dependent TREM2 signalling in myeloid cells: Molecular mechanisms and immunotherapeutic divergence in neurodegeneration and cancer.Clinical and translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe intratumoral heterogeneity and immunosuppressive microenvironment of hepatocellular carcinoma (HCC) significantly limit therapeutic efficacy. Although efferocytosis is fundamental for tissue homeostasis, its impact on the spatial architecture of the tumor microenvironment (TME) and patient prognosis in HCC remains uncharacterized.
methodsWe integrated single-cell RNA sequencing, spatial transcriptomics, and large-scale bulk datasets to construct an Efferocytosis-Related Scoring System (ERG score). We identified molecular subtypes and traced key cell subsets driving high-efferocytosis features. A robust prognostic model was established via large-scale machine learning screening (101 algorithms) and validated by in vitro experiments (qRT-PCR/Western Blot).
resultsThe ERG score indicates a specific immunosuppressive state driven by the High_ERGs_SPP1_Mac subpopulation. Spatially, this subpopulation physically co-localizes with malignant cells, potentially mediated by the MDK-SDC2 axis. The machine learning-derived risk score serves as a reliable quantitative indicator of High_ERGs_SPP1_Mac abundance, effectively predicting "cold tumor" phenotypes and immune checkpoint upregulation (e.g., PD-1, CTLA4). Additionally, experimental validation confirmed the upregulation of the core gene TPI1 (triosephosphate isomerase 1), aligning with the high glycolytic features of the high-risk subtype.
conclusionThe ERG scoring system offers a novel perspective for deconvoluting HCC heterogeneity. Our findings suggest that SPP1+ macrophages spatially reshape the TME, providing a theoretical basis for optimizing prognostic stratification and personalized immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.